Overview

Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer

Status:
Completed

Trial end date:
2019-03-02

Target enrollment:

Participant gender:

Summary

The purpose of the trial is to investigate the efficacy of metronomic treatment with daily oral vinorelbine in terms of clinical benefit rate based on local radiological assessment in patients with advanced/metastatic HR+/HER2- breast cancer resistant to endocrine therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Johannes Gutenberg University Mainz

Collaborator:

Pierre Fabre Pharma GmbH

Treatments:

Vinblastine
Vinorelbine